Standout Papers

Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive ... 2018 2026 2020 2023 505
  1. Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib (2018)
    Geoffrey R. Oxnard, Yuebi Hu et al. JAMA Oncology

Immediate Impact

1 from Science/Nature 61 standout
Sub-graph 1 of 22

Citing Papers

Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release
2024 Standout
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
2 intermediate papers

Works of Philip Tracy being referenced

Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
2018 Standout

Author Peers

Author Last Decade Papers Cites
Philip Tracy 467 349 208 6 526
Tzu‐Hsiu Tsai 461 367 182 17 596
Eamon M. Berge 418 301 228 14 532
Kelly Kugler 480 306 227 6 585
Minhao Fan 265 304 174 11 526
J. Zugazagoitia 367 282 216 5 509
Masaru Jida 270 248 269 14 464
Lorin A. Ferris 496 373 243 10 594
Adel Zaatar 368 324 124 9 467
Luigi Guetti 489 339 265 12 584
Antonella Flacco 475 377 264 13 611

All Works

Loading papers...

Rankless by CCL
2026